Peregrine Capital Management LLC Invests $7.84 Million in Xenon Pharmaceuticals Inc. $XENE

Peregrine Capital Management LLC acquired a new position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 174,851 shares of the biopharmaceutical company’s stock, valued at approximately $7,837,000. Peregrine Capital Management LLC owned 0.23% of Xenon Pharmaceuticals at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the period. Danske Bank A S purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $32,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Xenon Pharmaceuticals during the third quarter worth $39,000. State of Wyoming increased its position in shares of Xenon Pharmaceuticals by 112.8% during the third quarter. State of Wyoming now owns 1,151 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 610 shares during the period. Finally, Osaic Holdings Inc. increased its position in shares of Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft upped their price objective on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Stifel Nicolaus set a $66.00 price objective on Xenon Pharmaceuticals in a research report on Tuesday, February 10th. HC Wainwright upped their price objective on Xenon Pharmaceuticals from $53.00 to $74.00 and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Wedbush cut their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating on the stock in a research report on Monday, March 16th. Finally, Wolfe Research assumed coverage on Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 price objective on the stock. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $73.13.

Xenon Pharmaceuticals Price Performance

NASDAQ:XENE opened at $55.41 on Friday. The firm has a market capitalization of $4.61 billion, a PE ratio of -12.71 and a beta of 0.74. The business’s fifty day moving average price is $52.47 and its 200 day moving average price is $45.67. Xenon Pharmaceuticals Inc. has a 12 month low of $28.19 and a 12 month high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.11). During the same quarter in the previous year, the firm earned ($0.84) earnings per share. As a group, equities analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.83 EPS for the current year.

Insider Activity at Xenon Pharmaceuticals

In related news, insider Andrea Difabio sold 2,607 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $60.11, for a total value of $156,706.77. Following the transaction, the insider owned 4,893 shares of the company’s stock, valued at $294,118.23. This represents a 34.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Christopher John Kenney sold 2,771 shares of the stock in a transaction on Tuesday, March 10th. The shares were sold at an average price of $60.11, for a total value of $166,564.81. Following the completion of the transaction, the insider directly owned 4,729 shares in the company, valued at $284,260.19. This trade represents a 36.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 296,707 shares of company stock valued at $17,845,365 over the last quarter. 4.07% of the stock is owned by insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.